Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone

Abstract

BackgroundPancreatic cancer is a highly malignant tumor with a poor prognosis. Chemotherapy such as gemcitabine is still an important treatment. Gemcitabine (Gem) may prolong survival time and delay the development of recurrent disease after complete resection of pancreatic cancer. Currently, some control studies have been performed between certain drugs and gemcitabine monotherapy after pancreatic cancer surgery, but the outcomes were uncertain. Here, we implemented meta-analysis to compare the efficacy between adjuvant treatments and gemcitabine monotherapy in patients with resected pancreatic cancer.MethodsPubMed, Embase and the Central Registry of Controlled Trials of the Cochrane Library searches were undertaken to identify randomized controlled trials (RCTs). Date of search ranged from January 1997 to December 2017. The meta-analysis included six RCTs. The major endpoints involved overall survival (OS), disease-free survival/progress free survival/relapse-free survival (DFS/PFS/RFS) and grade 3–4 toxicity.ResultsPooled meta-analytic estimates were derived using random-effects model. Subgroup analysis used fixed-effects model. The outcome showed that there was no difference in OS (hazard ratio (HR), 0.87; 95% CI, 0.70–1.07; P = 0.19) and DFS (HR, 0.85; 95% CI, 0.71–1.02; P = 0.08) between the adjuvant treatments group (fluorouracil+folinic acid, S-1, gemcitabine+capecitabine, gemcitabine+erlotinib and gemcitabine+uracil/tegafur) and Gem monotherapy group. However, the subgroup analysis showed that only S-1 chemotherapy, which is an oral fluoropyrimidine agent containing tegafur, gimeracil and oteracil, was significant in OS (HR, 0.59; 95% CI, 0.46–0.74; P < 0.0001) and DFS (HR, 0.63; 95% CI, 0.52–0.75; P < 0.00001) compared with Gem alone. Toxicity analysis showed there was an increased incidence of grade 3/4 diarrhea (risk ratio (RR), 5.11; 95%CI, 3.24–8.05; P < 0.00001) and decreased incidence of grade 3/4 leucopenia (RR, 0.55; 95%CI, 0.31–0.98; P = 0.04), thrombocytopenia (RR, 0.61; 95%CI, 0.39–0.97; P = 0.04) in adjuvant treatments group. Neutropenia (RR, 0.69; 95%CI, 0.36–1.29; P = 0.24) and fatigue (RR, 1.29; 95%CI, 0.95–1.77; P = 0.11) for patients between the two groups were not significantly different.ConclusionsIn our meta-analysis, a significant survival benefit is only observed in the S-1 regimen, but the results are yet to be determined. Optimal cytotoxicity or targeted drug regimens need further validation in clinical trials in the future.Electronic supplementary materialThe online version of this article (10.1186/s12885-018-4948-7) contains supplementary material, which is available to authorized users.

A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC)

“…Secondly, because included studies used different survival measures (HR and survival duration) this study could not do formal statistical testing for consistency between direct and indirect comparisons. However, the credible intervals of all pooled HRs from network meta-analysis included CIs of corresponding HRs from direct comparisons by pairwise metaanalysis and the point estimates of HRs were also similar between the two meta-analyses, 21,79 supporting that there was no significant inconsistency between direct and indirect comparisons. Finally, this meta-analysis was done with summary statistics rather than individual patient data.…”

Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1–JNK axis

“…Hence, this malignant cancer will likely impose an increasing public health burden in the future. The highly intractable nature of pancreatic cancer is also demonstrated by its high probability of recurrence even after complete tumor resection ( 8 ), hence the need for novel therapeutic measures to prevent recurrence. Because CSCs have been identified in pancreatic cancer, a number of drugs that target molecules and pathways implicated in the control of pancreatic CSCs have been developed and advanced to clinical trials ( 9 , 10 ); however, none have reached clinical practice.…”

Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer

“…The preferred chemotherapy regimen for patients with PDAC is FOLFIRINOX (5-fluorouracil, calcium folinate, irinotecan, oxaliplatin) combined with gemcitabine and nab-paclitaxel [ 33 ], suggesting that folate may be a highly relevant molecule in the treatment and indicating that FR might be used as a molecular target. In contrast to the restricted FR expression found in normal tissues, many cancers, including pancreatic cancer, do express one or more FRs.…”